Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Target reached, but still looking for confirmation

Nanosonics
3:27pm
January 23, 2025
NAN provided a strong trading update and indicated its expectations to achieve the top-end of its FY25 guidance range. Questions remain around install base growth and budgetary pressures in the hospital which overhangs the stock ahead of a pending FDA approval and launch of the CORIS device. With a strong rally in the share price over the last month, our target price has been reached and as a result we pare our recommendation back to a Hold (from Add). While we see potential risk to the upside in FY25 guidance and outlook commentary at the result, we’re happy to see this play out to get more confidence on the hospital environment as well as timing around CORIS before getting more positive.

2Q25 update – An impressive performance

Generation Development Group
3:27pm
January 22, 2025
GDG delivered a very strong 2Q25 update, punctuated by record Investment bond sales of A$250m (a 3rd consecutive record quarter for the company). The key takeaway from the quarterly for us, is it confirmed the Investment Bond business appears to have delivered a step change in growth in recent quarters. We lift our GDG FY25F/FY26F EPS by 6%-10% on higher sales/FUM growth expectations in the Investment Bond business. Our PT rises to A$4.75 on our earnings changes and a lift to longer-term growth assumptions in our valuation. We think GDG has a great story, and management has executed very well. With the recent quarterly pointing to growth and sales momentum above our expectations, and the stock trading at a >10% discount to our PT, we move back to an ADD recommendation.

2Q25 result: Strong production, net debt increasing

BHP Group
3:27pm
January 22, 2025
A strong 2Q operating performance from BHP, with WAIO, BMA, NSWEC and Samarco all tracking to the upper half of FY25 production guidance. All guidance maintained, outside of Copper South Australia (modest revision). Net debt guided to US$11.5-$12.5bn at 31 December. Jansen Stage 1 remains on schedule and budget. We maintain an ADD rating for BHP and A$.10 target price (was A$).

2Q25 Result: East Wall Remediation Unlocks a Stronger Second Half

Northern Star Resources
3:27pm
January 21, 2025
2Q25 delivered 410koz of gold sales (307koz mined) at an AISC of A$2,128/oz, within our estimates. FY25 guidance has been maintained. KCGM East Wall Remediation is complete, unlocking the higher-grade Golden Pike North, which will drive 2H25 production and earnings. Growth at KCGM remains on track, engineering, design, construction progressing as scheduled. All major equipment has been delivered to site or country. The pending acquisition of De Grey Mining (DEG.ASX) reaffirms NST's commitment to growth.

Strong 2Q result through ramp up

Liontown Resources
3:27pm
January 21, 2025
LTR achieved a strong 2Q’FY25 operating result with production above expectations and unit operating costs below expectations. With unit operating costs lower than expectations, LTR was able to be net operating cash flow positive during the quarter. We maintain our Hold rating with an updated valuation-based target price of A$0.68ps (previously A$0.60ps).

Early commercialisation approaches, eyes on cash

Proteomics International Laboratories
3:27pm
January 21, 2025
PIQ has released its 2Q25 quarterly report. Key watch here is cash balance versus burn ahead of commercial launches of various new tests. Over the next few months, PIQ are anticipating the commercial launch of several tests internally in Australia prior to launching more broadly. Of particular interest to us is the endometriosis asset which is slated to launch next quarter (2Q’CY25) which shows strong clinical relevance and one we view has high commercial potential. Key here across all the new test launches will be more detail around commercial strategy / pricing etc. Regardless of the clinical relevance of the tests, PIQ has yet to prove it can effectively commercialise its assets. With a cash buffer of only two quarters, we see short-term downside risk. However, once addressed, news about test launches (albeit local launch = small market) could maintain investor interest with broader external licensing potential remaining the blue-sky opportunity. Happy to remain nimble here for now until funding is addressed, and commercial viability of its direct-to-consumer channel unfolds. We retain a cautious view until several issues are addressed.

Maintains positive momentum in 2Q

South32
3:27pm
January 20, 2025
S32 presented a healthy set of operational results in 2Q’FY25. Ongoing strength in alumina prices remains an important tailwind heading into H2, accounting for ~52% of group EBITDA in FY25. We maintain an ADD rating with a A$4.20 target price (was A$4.10).

IND placed on hold

Neurizon Therapeutics
3:27pm
January 17, 2025
NUZ has announced it has received notification from the FDA that its IND application for its Ph2/3 enabling trial has been placed on clinical hold, with questions to come around sufficiency of safety data in humans. This was unexpected given the safety profile shown in the Ph1 and continued safe use throughout the extension study in patients. Regardless, it’s now on hold and depending on the questions to be received - is likely to halt progression into its adaptive Ph2/3 trial in ALS by at least a month to several months. It’s difficult to determine the impact of the delay. We don’t see any reasons to jump at shadows right now but equally happy to wait until we know the scope of the questions to better understand what is missing in the submission and potential impact to timelines. Expect to know more in the coming weeks. No changes to our forecasts at this stage, with our assumptions of clinical progress based on significantly longer timeframes versus company expectations.

Strong finish in 4Q but inflation persists

Rio Tinto
3:27pm
January 16, 2025
RIO delivered a good 4Q result with iron ore shipments in line and bauxite and copper output beating estimates. Pilbara iron ore unit cash costs are expected at the upper end of $21.75-$23.50/t. We maintain an ADD rating on RIO, viewing its mix as an attractive mix of metals. With an updated A$125 per share Target Price (was A$129ps).

2Q25 Result: Consistency and Cash Generation

Catalyst Metals
3:27pm
January 16, 2025
2Q25 delivered 28.3koz of gold production, with 28.5koz aligning with expectations. Guidance remains unchanged. The legacy debt position has been fully repaid, and CYL is now both debt-free and hedge-free. Unit costs continue to systematically decrease, supporting the company’s 3-year growth strategy to achieve production of over 200koz by FY27. We maintain our Speculative Buy recommendation and have raised our price target to A$4.04 per share (previously A$4.01 per share), reflecting adjustments to Morgans’ AUD:USD FX assumptions.

News & Insights

Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more
The U.S. and China, through negotiations led by the Chinese Deputy Premier and U.S. Treasury Secretary Scott Bessent, agreed to a 90-day tariff reduction from over 125% to 30% and 10% respectively

US and Chinese actions had led to an unintended embargo of trade between the world’s two largest economies.

In recent days there has been discussion of the temporary “cease fire” in the tariff war between the US and China.

The situation was that both countries had levied tariffs on each other more than 125%. This had led to a mutual embargo of trade between the two world is two largest economies. Then as a result of negotiation between the Deputy Premier of China and US Treasury Secretary Scott Bessent both China and the US agreed to a 90 day pause in “hostilities” where both sides agreed to reduce the US tariff on the China to 30 percent and the Chinese tariff on the US to 10%.

Some suggested that this meant that “China had won” others suggested that the “US had won.” To us this really suggests that both parties were playing in a different game. The was a game in which both sides had won.

To understand why this is the case we must understand a little of the theory of this type of competition. Economists usually use discuss competition in terms of markets where millions of people are involved. In such a case we find a solution by finding the intersection of supply and demand which model the exchange between vast numbers of people.

But here we are ware talking of a competition where only two parties are involved.

When exceedingly small numbers like this are involved, we find the solution to the competition by what is called “Game Theory.”

In this game there are only two players. One is called China, and the other is called the US. Game theory teaches us that are there three different types of games. The first is a zero-sum game. In this game there two sides are competing over a fixed amount of product. Again, this is called " A zero sum game “. Either one party gets a bigger share of the total sum at stake and the other side gets less. This zero-sum game is how most of the Media views the competition between the US and China.

A second form is a decreasing sum game. An example of this is a war. Some of the total amount that is fought over is destroyed in the process. Usually both sides will wind up worse than when they started.

Then there is a third form. This form is called an ‘increasing sum game.’ This is where both sides cooperate so that the total sum in the game grows because of this cooperation. We think that what happened in the US and China negotiation was an increasing sum game.

As Scott Bessent said at the Saudi Investment Forum in Riyadh soon after the agreement was signed, “both sides came with a clear agenda with shared interests and great mutual respect.”

He said, “after the weekend, we now have a mechanism to avoid escalation like we had before. We both agreed to bring the tariff levels down by 115% which I think is very productive because where we were with 145% and 125% was an unintended embargo. That is not healthy for the two largest economies in the world.”

He went on, “when President Trump began the tariff program, we had a plan, we had a process. What we did not have with the Chinese was a mechanism. The Vice Premier and I now call this the ‘Geneva mechanism’”.

Both sides cooperated to make both sides better off. Bessent added “what we do not want, and both sides agreed, is a generalised decoupling between the two largest economies in the world. What we want is the US to decouple in strategic industries, medicine, semiconductors, other strategic areas. As to other countries; we have had very productive discussions with Japan, South Korea, Indonesia, Taiwan, Thailand. Europe may have collective action problems with the French wanting one thing and the Italians wanting a different thing. but I am confident that with Europe, we will arrive at a satisfactory conclusion.

We have a very good framework. I think we can proceed from here.”

What we think we can see here is that the United States and China have cooperated to both become better off. This is what we call an increasing sum game.

They will continue their negotiation using that approach. This will do much to allay the concerns that so many had about the effect of these new tariffs.

Read more